18 11, 2019

MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis.

2019-12-10T11:19:14+01:00November 18th, 2019|biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, osteomiR, osteoporosis, Personalized medicine|0 Comments

We want to draw your attention to the latest publication of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in AUVA Research Center, in cooperation with TAmiRNA GmbH, in Bone. "MicroRNA levels in bone and blood change during bisphosphonate and teriparatide therapy in an animal model of postmenopausal osteoporosis." Kocijan R, Weigl M, Skalicky S, et al. Bone 2019 Volume 131, February 2020, 115104. https://doi.org/10.1016/j.bone.2019.115104 Take the chance and download the paper

7 11, 2019

Serum microRNA as novel biomarkers for osteoporotic vertebral fractures.

2019-11-18T11:03:22+01:00November 7th, 2019|biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, osteomiR, osteoporosis, Personalized medicine|0 Comments

We want to draw your attention to the latest publication of the Department of Oncology and Metabolism, University of Sheffield, United Kingdom, in cooperation with TAmiRNA GmbH, in Bone. "Serum microRNA as novel biomarkers for osteoporotic vertebral fractures." Zarecki P, Hackl M, Grillari J, et al. Bone 2019 Oct 24:115105. doi: 10.1016/j.bone.2019.115105. Specific circulating miRNAs reflect the presence of osteoporotic vertebral fractures in postmenopausal women. They are unlikely to reflect low BMD, and more likely changes in bone quality or fracture healing. Take the chance and download this paper for free before December 25, 2019 by clicking here

5 11, 2019

Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues

2019-12-10T12:04:11+01:00November 5th, 2019|biomarker, biomarkers, drug development, drug discovery, LMD, microRNAs, Personalized medicine, safety, Vivomicx|0 Comments

We want to draw your attention to the latest publication with our partner Vivomicx. Together we have developed a combination of laser microdissection (LMD) and high quality qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues. Using this protocol TAmiRNA & Vivomicx have been able to demonstrate: the profound difference of RNA expression between whole tumor and subsets of cells within the tumor and the large heterogeneity in RNA expression between colorectal* tumor compartments such as tumor, stroma and tumor endothelial cells. * Note: the technology can be utilized for almost any tissue sample. Our new approch allows to: Discover differential expression patterns between “healthy” and “diseased” tissues on the cellular level; [...]

30 03, 2019

Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures.

2019-12-09T09:19:55+01:00March 30th, 2019|biomarker, Liver disease, microRNAs, Personalized medicine|0 Comments

We want to draw your attention to the latest publication of the Department of Surgery, Medical University of Vienna, in cooperation with TAmiRNA GmbH, in Hepatology. "Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures." Hepatology. 2019 Jun;69(6):2636-2651. Personalized medicine in liver surgery. Together with colleagues from Medical University Vienna we could show that plasma levels of three miRNAs can accurately predict liver dysfunction prior to surgery. This will allow us to stratify patients into risk groups that need preoperative liver volume augmentation or might even be better off with alternative treatment options. Click here to read the study

16 05, 2018

Improving Quality Of Life For Patients With Osteoporosis Using MicroRNAs

2019-12-09T09:18:10+01:00May 16th, 2018|aging, biomarker, biomarkers, bone fracture risk assessment, microRNAs, osteomiR|0 Comments

We want to draw your attention to our latest article “Improving Quality Of Life For Patients With Osteoporosis Using MicroRNAs” Our simulations provide evidence for the utility of the osteomiR™ test for fracture risk assessment, and, furthermore, highlight the general potential of circulating microRNAs to be exploited as minimal-invasive diagnostic tools. Click here to read the study

27 04, 2018

New evidence for associations between miRNAs and metabolic unhealthy conditions

2019-10-16T09:22:36+02:00April 27th, 2018|aging, biomarker, biomarkers, microRNAs|0 Comments

We want to draw your attention to the latest publication in cooperation with TAmiRNA GmbH, in Obesity Surgery.” Reduction of Premature Aging Markers After Gastric Bypass Surgery in Morbidly Obese Patients.” The findings indicate a significant reduction of the proinflammatory SASP after bariatric surgery. An increase in telomere length and reduced oxidative stress at telomeres was observed. Moreover, miR10a-5p which is downregulated during aging was upregulated after surgery. Click here to read the study

21 03, 2018

Serum levels of bone-related microRNAs and their association to bone microstructure and histomorphometry

2019-10-16T09:22:50+02:00March 21st, 2018|biomarker, bone diseases, microRNAs, microstructure, standard tools|0 Comments

We want to draw your attention to the latest publication of the VINFORCE research Group in cooperation with TAmiRNA GmbH, in Scientific Reports from Nature. “Bone-related circulating microRNAs miR-29b-3p, miR-550a-3p, and miR-324-3p and their association to bone microstructure and histomorphometry.” Scientific Reports, Volume 8,4867 (2018) MicroRNAs are promising new biomarkers for bone diseases. The findings enhance the potential value of circulating miRNAs as bone biomarkers and the clinical utility of miRNAs to reflect dynamic changes in bone formation and microstructure. Click here to read the study

10 01, 2018

New evidence that microRNA bone biomarkers can improve early diagnosis of osteoporosis

2019-10-16T09:23:20+02:00January 10th, 2018|bone fracture risk assessment, female, microRNA, microRNAs, standard tools|0 Comments

We would like to draw your attention to our lastest publication: “Cost-utility analysis of fracture risk assessment using microRNA compared with Standard Tools and no Monitoring in the Austrian female Population.” Bone. Volume 108, 2018; Pages 44-54. This study presents the first comprehensive attempt to model the cost-effectiveness of circulating microRNAs for bone fracture risk assessment in a central European female post-menopausal population in comparison to DXA and FRAX®. The results demonstrate that the osteomiR™ test can be a cost-effective alternative to established risk assessment strategies. Click here to read the study